[go: up one dir, main page]

AU7676300A - Human anti-adipocyte monoclonal antibodies and their use - Google Patents

Human anti-adipocyte monoclonal antibodies and their use

Info

Publication number
AU7676300A
AU7676300A AU76763/00A AU7676300A AU7676300A AU 7676300 A AU7676300 A AU 7676300A AU 76763/00 A AU76763/00 A AU 76763/00A AU 7676300 A AU7676300 A AU 7676300A AU 7676300 A AU7676300 A AU 7676300A
Authority
AU
Australia
Prior art keywords
adipocyte
monoclonal antibodies
human anti
human
monoclonal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU76763/00A
Inventor
Bryan Michael Edwards
Sarah Helen Main
Tristan John Vaughan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
Original Assignee
Cambridge Antibody Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Antibody Technology Ltd filed Critical Cambridge Antibody Technology Ltd
Publication of AU7676300A publication Critical patent/AU7676300A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU76763/00A 1999-10-12 2000-10-11 Human anti-adipocyte monoclonal antibodies and their use Abandoned AU7676300A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15881299P 1999-10-12 1999-10-12
US60158812 1999-10-12
PCT/GB2000/003900 WO2001027279A1 (en) 1999-10-12 2000-10-11 Human anti-adipocyte monoclonal antibodies and their use

Publications (1)

Publication Number Publication Date
AU7676300A true AU7676300A (en) 2001-04-23

Family

ID=22569814

Family Applications (1)

Application Number Title Priority Date Filing Date
AU76763/00A Abandoned AU7676300A (en) 1999-10-12 2000-10-11 Human anti-adipocyte monoclonal antibodies and their use

Country Status (2)

Country Link
AU (1) AU7676300A (en)
WO (1) WO2001027279A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20010408A1 (en) 2001-07-10 2003-01-10 Univ Napoli Federico Ii CYTOTOXIC HUMAN MINI-ANTIBODY FOR CANCER CELLS THAT EXPRESS THE ERBB2 RECEPTOR.
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
GB2389362B (en) * 2002-06-05 2006-02-15 Walcom Animal Science Antibodies to adipose tissues
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
JP4836451B2 (en) 2002-07-18 2011-12-14 メルス ベー ヴェー Recombinant production of antibody mixtures
AU2013200009B2 (en) * 2002-07-18 2015-05-07 Merus N.V. Recombinant production of mixtures of antibodies
AU2003288675B2 (en) 2002-12-23 2010-07-22 Medimmune Limited Antibodies against PD-1 and uses therefor
CN102040662A (en) 2003-03-14 2011-05-04 惠氏有限责任公司 Antibodies against human IL-21 receptor and uses therefor
AU2004239065B2 (en) * 2003-05-14 2008-05-15 Domantis Limited A process for recovering polypeptides that unfold reversibly from a polypeptide repertoire
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
WO2004106375A1 (en) 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Fab library for the preparation of anti vegf and anti rabies virus fabs
EP1737971B1 (en) 2004-01-20 2017-08-16 Merus N.V. Mixtures of binding proteins
GB0414886D0 (en) * 2004-07-02 2004-08-04 Neutec Pharma Plc Treatment of bacterial infections
JP5096167B2 (en) 2005-01-24 2012-12-12 メドイミューン リミテッド Specific binding member for NGF
ES2664218T3 (en) * 2007-06-01 2018-04-18 Open Monoclonal Technology, Inc Compositions and methods of inhibiting endogenous immunoglobulin genes and producing transgenic human idiotypic antibodies
CL2008002153A1 (en) * 2007-07-24 2009-06-05 Amgen Inc Isolated antibody or antigen-binding fragment thereof that binds to the yl-18 (yl-18r) receptor; encoding nucleic acid molecule; host cell comprising it; pharmaceutical composition; medical use to treat or prevent a condition associated with il-18r; In vitro method to inhibit the binding of yl-18 to yl-18r.
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof
KR101346530B1 (en) * 2009-03-20 2013-12-31 암젠 인크 Alpha-4-beta-7 heterodimer specific antagonist antibody
CA2871068C (en) 2012-04-20 2022-06-14 Merus B.V. Methods and means for the production of ig-like molecules
US11007266B2 (en) * 2017-07-11 2021-05-18 University Of Macau Method of mitigating cardiovascular hypertrophy and perivascular fibrosis induced by angiotensin II
BR112020016944A2 (en) * 2018-02-20 2020-12-15 Dragonfly Therapeutics, Inc. ANTIBODY VARIABLE DOMAINS THAT TARGET CD33 AND THE USE OF THE SAME

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5102658A (en) * 1985-07-19 1992-04-07 National Research Development Corporation Antibody treatment for adiposity
GB9120037D0 (en) * 1991-09-19 1991-11-06 Nat Res Dev Immunological control of fat

Also Published As

Publication number Publication date
WO2001027279A1 (en) 2001-04-19

Similar Documents

Publication Publication Date Title
AU1462300A (en) Human pan-hcv human monoclonal antibodies
AU1704099A (en) Monoclonal human natural antibodies
AU7676300A (en) Human anti-adipocyte monoclonal antibodies and their use
AU2001256325A1 (en) Human and humanized fap-alpha-specific antibodies
AU2002220843A1 (en) Humanised antibodies and uses thereof
IL223047A (en) Antibody comprising an fc region and uses thereof
AU1682699A (en) Monoclonal antibody against connective tissue growth factor and medicinal uses thereof
EP1071458A4 (en) Humanized antibody and uses thereof
GB9927332D0 (en) Novel antibody and uses thereof
AU5441000A (en) Human monoclonal antibody
AU3159499A (en) Antigen preparation and use
AU2608602A (en) Silensed anti-cd28 antibodies and use thereof
AU6232300A (en) Receptors and associated proteins
AU1608201A (en) Human zven proteins
HUP9800613A3 (en) Humanized antibody against human fas-antigene
EP0977590A4 (en) Human monoclonal antibodies
AU4483500A (en) Human membrane-associated proteins
AU2136401A (en) P450rai-2 and related proteins
AU2669201A (en) Taccalonolides and their use
AU6227800A (en) Recombinant antibody directed against human sperm antigen
AU2567599A (en) Anti-ccr1 antibodies and methods of use therefor
AU2430901A (en) Human lyases and associated proteins
GB9901689D0 (en) Therapeutic antibody composition and use
GB9906754D0 (en) Therapeutic antibody composition and use
GB9907151D0 (en) Therapeutic antibody composition and use

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase